ICOS and OX40 tandem co-stimulation enhances CAR T-cell cytotoxicity and promotes T-cell persistence phenotype

Chimeric Antigen Receptor (CAR) T-cell therapies have emerged as an effective and potentially curative immunotherapy for patients with relapsed or refractory malignancies. Treatment with CD19 CAR T-cells has shown unprecedented results in hematological malignancies, including heavily refractory leuk...

Full description

Bibliographic Details

Published in:	Frontiers in Oncology
Main Authors:	Eider Moreno-Cortes, Pedro Franco-Fuquen, Juan E. Garcia-Robledo, Jose Forero, Natalie Booth, Januario E. Castro
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-08-01
Subjects:	adoptive immunotherapy chimeric antigen receptor cell-and tissue-based therapy T-cell activation costimulatory molecules
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2023.1200914/full